MA41197B1 - Traitement de le pemphigus - Google Patents
Traitement de le pemphigusInfo
- Publication number
- MA41197B1 MA41197B1 MA41197A MA41197A MA41197B1 MA 41197 B1 MA41197 B1 MA 41197B1 MA 41197 A MA41197 A MA 41197A MA 41197 A MA41197 A MA 41197A MA 41197 B1 MA41197 B1 MA 41197B1
- Authority
- MA
- Morocco
- Prior art keywords
- pemphigus
- corticosteroids
- therapy
- relates
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
La présente invention concerne des procédés de traitement, avec un inhibiteur de btk, d'une maladie bulleuse, en particulier du pemphigus vulgaire ou du pemphigus foliacé chez un mammifère, l'utilisation d'un inhibiteur de btk en tant que thérapie de remplacement d'une thérapie par corticoïdes pour les maladies pouvant être traitées avec des corticoïdes, telles qu'une maladie auto-immune ou une maladie inflammatoire et en particulier lorsque des corticoïdes sont utilisés comme thérapie de première ou de seconde ligne. La présente invention concerne également des formulations pharmaceutiques comprenant ces inhibiteurs de btk.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462093891P | 2014-12-18 | 2014-12-18 | |
PCT/US2015/066868 WO2016100914A1 (fr) | 2014-12-18 | 2015-12-18 | Traitement du pemphigus |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41197B1 true MA41197B1 (fr) | 2021-01-29 |
Family
ID=55080225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41197A MA41197B1 (fr) | 2014-12-18 | 2015-12-18 | Traitement de le pemphigus |
Country Status (15)
Country | Link |
---|---|
US (2) | US10485797B2 (fr) |
EP (1) | EP3233103B1 (fr) |
CN (1) | CN107257686B (fr) |
AU (2) | AU2015364335B2 (fr) |
BR (1) | BR112017013022A2 (fr) |
CA (1) | CA2970723C (fr) |
EA (1) | EA036269B1 (fr) |
ES (1) | ES2843323T3 (fr) |
IL (1) | IL252839B (fr) |
MA (1) | MA41197B1 (fr) |
MX (1) | MX2017007973A (fr) |
PL (1) | PL3233103T3 (fr) |
PT (1) | PT3233103T (fr) |
SG (1) | SG11201704808VA (fr) |
WO (1) | WO2016100914A1 (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA027213B9 (ru) | 2012-09-10 | 2017-09-29 | Принсипиа Биофарма Инк. | Соединения пиразолопиримидина в качестве ингибиторов киназ |
JP6204568B2 (ja) | 2013-04-25 | 2017-09-27 | ベイジーン,リミテッド | タンパク質キナーゼ阻害剤としての縮合複素環化合物 |
MX2016003292A (es) | 2013-09-13 | 2016-06-24 | Beigene Ltd | Anticuerpos anti-muerte programada 1 y su uso como terapeuticos y diagnosticos. |
KR20160117614A (ko) | 2014-02-21 | 2016-10-10 | 프린시피아 바이오파마, 인코퍼레이티드 | Btk 억제제의 염 및 고체 형태 |
JP6526189B2 (ja) | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | 抗pd−l1抗体並びにその治療及び診断のための使用 |
SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
WO2016210165A1 (fr) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Inhibiteurs de la tyrosine kinase |
EP3478273A1 (fr) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc. | Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
CA3033827A1 (fr) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Forme cristalline de (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyle)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, sa preparation et ses utilisations |
AU2017313085A1 (en) | 2016-08-19 | 2019-03-14 | Beigene Switzerland Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
CN111333656B (zh) | 2016-12-15 | 2023-03-14 | 豪夫迈·罗氏有限公司 | 制备btk抑制剂的方法 |
CN108329274B (zh) * | 2017-01-13 | 2021-09-03 | 正大天晴药业集团股份有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
EP3573989A4 (fr) * | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | Formes cristallines de (s) -7- (1- (but-2-ynoyl) pipéridin-4-yl) -2- (4-phénoxyphényl) -4, 5, 6, 7-tétrahy dropyrazolo [1, 5-a]pyrimidine-3-carboxamide, préparation et utilisations associées |
CN108727404B (zh) * | 2017-04-14 | 2020-05-12 | 中国科学院上海药物研究所 | 噻吩并[3,2-d]嘧啶类化合物、其制备方法及用途 |
AU2018290532A1 (en) | 2017-06-26 | 2019-11-21 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
WO2019108795A1 (fr) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Traitement de lymphomes à cellules b indolentes ou agressives au moyen d'une combinaison comprenant des inhibiteurs de btk |
WO2019208805A1 (fr) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | AGENT PRÉVENTIF ET/OU THÉRAPEUTIQUE POUR MALADIE AUTO-IMMUNE COMPRENANT UN COMPOSÉ AYANT UNE ACTIVITÉ INHIBITRICE DE Btk EN TANT QUE PRINCIPE ACTIF |
SG11202102116XA (en) * | 2018-09-18 | 2021-04-29 | Beijing Innocare Pharma Tech Co Ltd | Crystalline forms of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide |
EP3876911A4 (fr) * | 2018-11-06 | 2022-06-22 | Beijing InnoCare Pharma Tech Co., Ltd. | Dispersion solide amorphe de 6-(1-acryloylpipéridine-4-yl)-2-(4-phénoxyphényl) nicotinamide |
CN109939223B (zh) * | 2019-04-04 | 2020-04-07 | 中南大学湘雅二医院 | 一种白介素2在制备用于治疗寻常型天疱疮口腔糜烂药物的应用 |
TW202128172A (zh) | 2019-10-09 | 2021-08-01 | 美商普林斯匹亞生物製藥公司 | 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(環氧丙烷‐3‐基)哌嗪-1-基]戊-2-烯腈治療天皰瘡的方法 |
JP2022550919A (ja) | 2019-10-14 | 2022-12-05 | プリンシピア バイオファーマ インコーポレイテッド | (r)-2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペンタ-2-エンニトリルを投与することにより免疫性血小板減少症を治療する方法 |
CN115605181A (zh) | 2020-01-08 | 2023-01-13 | 普林斯匹亚生物制药公司(Us) | 包含2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)-1H-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4,4-二甲基戊-2-烯腈的局部药物组合物 |
WO2021207662A1 (fr) * | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Utilisation d'il-22-fc pour le traitement ou la prévention de la pneumonie, du syndrome de détresse respiratoire aiguë ou du syndrome de libération de cytokines |
CN117279641A (zh) | 2021-04-16 | 2023-12-22 | 普林斯匹亚生物制药公司 | 通过施用特定化合物治疗药物和疫苗诱导的免疫性血小板减少症的方法 |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4082819A (en) | 1977-03-02 | 1978-04-04 | The Standard Oil Company | Rubber-modified acrylonitrile-vinyl ether-indene polymers |
JPS5663950A (en) | 1979-10-30 | 1981-05-30 | Mitsubishi Chem Ind Ltd | Cyclopropanecarboxylic ester |
FR2535721A1 (fr) | 1982-11-08 | 1984-05-11 | Sanofi Sa | Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
JPS623848A (ja) | 1985-06-28 | 1987-01-09 | Nippon Steel Corp | 疲労強度のすぐれたスタツド付きフラツシユバツト溶接アンカ−チエ−ン |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
JP2518353B2 (ja) | 1988-06-09 | 1996-07-24 | 住友化学工業株式会社 | シアノ酢酸アミド誘導体およびその製造中間体 |
CA2018801C (fr) | 1990-06-12 | 2000-08-22 | Pierre Louis Beaulieu | Derives peptidiques comprenant une terminaison-n1,4-dioxo-c4 |
JPH04177244A (ja) | 1990-11-10 | 1992-06-24 | Konica Corp | ハロゲン化銀写真感光材料 |
CA2033447C (fr) | 1990-12-31 | 1999-08-31 | Robert Deziel | Complexe synergique pour le traitement des infections herpetiques |
DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
JPH05301838A (ja) | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
WO1995024190A2 (fr) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant |
JPH0827090A (ja) | 1994-05-13 | 1996-01-30 | Sumitomo Chem Co Ltd | シアノ酢酸アミド誘導体、その用途およびその製造中間体 |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
PL335839A1 (en) | 1997-03-14 | 2000-05-22 | Basf Ag | Cycloalkylalkane carboxamides as well as their production and application |
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
IL125947A0 (en) | 1997-09-17 | 1999-04-11 | American Cyanamid Co | 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents |
DK1021171T3 (da) | 1997-10-09 | 2003-08-25 | Dexcel Pharma Technologies Ltd | Lægemiddelfremførelsessystem til forsinket, fuldstændig frigivelse gastrointestinalt |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
EP1169038B9 (fr) | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Inhibiteurs cycliques de proteine tyrosine kinase |
SK3812002A3 (en) | 1999-09-17 | 2003-09-11 | Abbott Gmbh & Co Kg | Pyrazolopyrimidines as therapeutic agents |
WO2001072751A1 (fr) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines utilisees comme inhibiteurs de tyrosine kinases |
AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
US7244744B2 (en) | 2001-11-01 | 2007-07-17 | Icagen, Inc. | Piperidines |
JP3991812B2 (ja) | 2001-12-11 | 2007-10-17 | 住友化学株式会社 | エステル化合物およびその用途 |
WO2003068157A2 (fr) | 2002-02-11 | 2003-08-21 | The Brigham And Women's Hospital, Inc. | Inhibiteurs de kinase et leurs procedes d'utilisation |
NI200300043A (es) | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
GB0219024D0 (en) | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
GB0226370D0 (en) | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
CA2516234A1 (fr) | 2003-02-21 | 2004-09-02 | Pfizer Inc. | Derives d'amino-thiazole substitues par n-heterocyclyle en tant qu'inhibiteurs de la proteine kinase |
US20050008640A1 (en) | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
JP4727579B2 (ja) | 2003-08-01 | 2011-07-20 | 中外製薬株式会社 | マロニル−CoAデカルボキシラーゼ阻害剤として有用なシアノアミド化合物 |
MXPA06002455A (es) | 2003-09-02 | 2006-08-31 | Pfizer Prod Inc | Formas de dosificacion de liberacion sostenida de ziprasidona. |
WO2005023773A1 (fr) | 2003-09-04 | 2005-03-17 | Pfizer Limited | Procede pour la preparation d'arylpyrazoles substitues |
GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
CA2539976A1 (fr) | 2003-09-25 | 2005-04-07 | Warner-Lambert Company Llc | Procedes de mise en oeuvre d'acides amines a affinite pour la proteine a2d |
US20060025383A1 (en) | 2004-02-03 | 2006-02-02 | Neil Wishart | Aminobenzoxazoles as therapeutic agents |
JP4552456B2 (ja) | 2004-02-27 | 2010-09-29 | 住友化学株式会社 | エステル化合物およびその用途 |
JPWO2005085210A1 (ja) | 2004-03-10 | 2008-01-17 | 小野薬品工業株式会社 | ニトリル化合物およびその化合物を有効成分として含有する医薬組成物 |
US7807719B2 (en) | 2004-09-14 | 2010-10-05 | Chaim Roifman | Compounds useful for modulating abnormal cell proliferation |
EP1794137A4 (fr) | 2004-09-27 | 2009-12-02 | Kosan Biosciences Inc | Inhibiteurs de kinases specifiques |
AU2006213746A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods |
EP1863449A2 (fr) | 2005-03-28 | 2007-12-12 | Dexcel Pharma Technologies Ltd. | Absorption regulee de statines dans l'intestin |
AU2006343359A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
US20080176865A1 (en) | 2005-06-15 | 2008-07-24 | Pfizer Limited | Substituted arylpyrazoles |
US20080146643A1 (en) | 2005-06-15 | 2008-06-19 | Pfizer Limited | Combination |
US7645786B2 (en) | 2005-06-15 | 2010-01-12 | Pfizer Inc. | Substituted arylpyrazoles |
US20070149464A1 (en) | 2005-06-15 | 2007-06-28 | Pfizer Inc. | Combination |
AU2006257647A1 (en) | 2005-06-15 | 2006-12-21 | Pfizer Limited | Substituted arylpyrazoles for use against parasites |
GB0517205D0 (en) | 2005-08-22 | 2005-09-28 | Novartis Ag | Organic compounds |
EP1932833B1 (fr) | 2005-10-07 | 2012-08-01 | Kissei Pharmaceutical Co., Ltd. | Compose heterocyclique azote et composition pharmaceutique le contenant |
CN101448506A (zh) | 2005-12-02 | 2009-06-03 | 拜尔健康护理有限责任公司 | 通过抑制有丝***酶激酶治疗癌症的吡咯并三嗪衍生物 |
CN101421269A (zh) | 2006-01-13 | 2009-04-29 | 环状药物公司 | 酪氨酸激酶抑制剂及其用途 |
WO2007115269A2 (fr) | 2006-03-31 | 2007-10-11 | The Board Of Regents Of The University Of Texas System | Médicaments anticancéreux biodisponibles par voie orale associés à l'acide caféique |
US7645748B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
AU2007257423B8 (en) | 2006-05-31 | 2012-02-16 | The Regents Of The University Of California | Purine analogs |
WO2008005954A2 (fr) | 2006-06-30 | 2008-01-10 | The Board Of Regents Of The University Of Texas System | Modulateurs de protéine signal en tant qu'agents thérapeutiques |
ATE523499T1 (de) | 2006-07-06 | 2011-09-15 | Array Biopharma Inc | Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer |
DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
CA2668286C (fr) | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Sonde d'activite de la tyrosine kinase de bruton et son procede d'utilisation |
AU2007323335A1 (en) | 2006-11-23 | 2008-05-29 | Novartis Ag | Pyrimidines and their use as CXCR2 receptor antagonists |
EP2125819B1 (fr) | 2007-03-21 | 2014-10-22 | Bristol-Myers Squibb Company | Composés hétérocycliques fusionnés utiles pour le traitement de maladies prolifératives, allergiques, auto-immunes ou inflammatoires |
GB2447933A (en) | 2007-03-27 | 2008-10-01 | Chemence Ltd | Cyanoacrylate monomer for forming an adhesive polymer |
CN101674834B (zh) | 2007-03-28 | 2013-06-12 | 环状药物公司 | 布鲁顿氏酪氨酸激酶(Bruton's tyrosine kinase)抑制剂 |
MX2010008198A (es) | 2008-02-25 | 2010-08-23 | Hoffmann La Roche | Inhibidores de cinasa de pirrolopirazina. |
PT2250172E (pt) | 2008-02-25 | 2011-11-30 | Hoffmann La Roche | Inibidores de pirrolpirazina-cinase |
WO2009140128A2 (fr) | 2008-05-13 | 2009-11-19 | Irm Llc | Composés et compositions servant d'inhibiteurs de kinases |
JP2011520986A (ja) | 2008-05-22 | 2011-07-21 | アムジエン・インコーポレーテツド | タンパク質キナーゼ阻害薬としての複素環類 |
US20110224235A1 (en) | 2008-07-16 | 2011-09-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
EP2324020A2 (fr) | 2008-08-01 | 2011-05-25 | Biocryst Pharmaceuticals, Inc. | Dérivés de pipéridine comme inhibiteurs de jak3 |
US8450337B2 (en) | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
US20120028981A1 (en) | 2008-11-05 | 2012-02-02 | Principia Biopharma Inc. | Kinase Knockdown Via Electrophilically Enhanced Inhibitors |
US20100113520A1 (en) | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
TW201609747A (zh) | 2009-09-09 | 2016-03-16 | 阿維拉製藥公司 | Pi3激酶抑制劑及其用途 |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
JP2013510886A (ja) | 2009-11-16 | 2013-03-28 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア | キナーゼ阻害剤 |
WO2011144585A1 (fr) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Dérivés de pyrrolo[2,3-b]pyrazine-7-carboxamide et leur utilisation comme inhibiteurs de jak et syk |
WO2011152351A1 (fr) | 2010-05-31 | 2011-12-08 | 小野薬品工業株式会社 | Dérivé de purinone |
US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
NZ772688A (en) | 2010-06-03 | 2022-09-30 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
CN101880243A (zh) | 2010-06-04 | 2010-11-10 | 贵阳柏丝特化工有限公司 | 一种含氟氰拟除虫菊酯化合物及其合成方法与用途 |
KR20130099040A (ko) | 2010-08-10 | 2013-09-05 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Btk 억제제의 베실레이트 염 |
MX347040B (es) | 2011-05-17 | 2017-04-10 | Principia Biopharma Inc | Inhibidores de tirosina-cinasas. |
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
WO2012158810A1 (fr) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Inhibiteurs de tyrosine kinase |
KR102052670B1 (ko) | 2011-05-17 | 2019-12-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키나아제 저해제 |
US8828426B2 (en) | 2011-06-07 | 2014-09-09 | Zx Pharma, Llc | Multiparticulate L-carnitine compositions and related methods |
US20130178483A1 (en) | 2011-06-28 | 2013-07-11 | Pharmacyclics, Inc. | Methods and Compositions for Inhibition of Bone Resorption |
AU2012283775A1 (en) | 2011-07-13 | 2014-01-23 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
MY192354A (en) * | 2011-07-19 | 2022-08-17 | Merck Sharp & Dohme | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
US20140155406A1 (en) | 2011-07-19 | 2014-06-05 | Petrus Antonius De Adrianus Man | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk inhibitors |
EP2548877A1 (fr) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK |
EP2760863A1 (fr) | 2011-09-20 | 2014-08-06 | Cellzome Limited | Dérivés de pyrazolo[4,3-c]pyridine comme inhibiteurs de kinases |
EA032463B1 (ru) | 2011-10-19 | 2019-05-31 | Фармасайкликс Элэлси | Применение ингибиторов тирозинкиназы брутона (втк) |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
US9353087B2 (en) * | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
CA2874461C (fr) | 2012-06-18 | 2021-10-12 | Principia Biopharma Inc. | Pyrrolopyrimidines ou pyrazolopyrimidines covalentes reversibles utiles pour le traitement du cancer et de maladies auto-immunes |
US20150140085A1 (en) | 2012-06-29 | 2015-05-21 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
US9572811B2 (en) | 2012-08-03 | 2017-02-21 | Principia Biopharma Inc. | Treatment of dry eye |
EA027213B9 (ru) | 2012-09-10 | 2017-09-29 | Принсипиа Биофарма Инк. | Соединения пиразолопиримидина в качестве ингибиторов киназ |
MD20150035A2 (ro) | 2012-11-02 | 2015-10-31 | Pfizer Inc. | Inhibitori de tirozinkinaza Bruton |
JP2015537033A (ja) | 2012-11-15 | 2015-12-24 | ファーマサイクリックス,インク. | キナーゼ阻害剤としてのピロロピリミジン化合物 |
US20140142099A1 (en) | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
JP6162904B2 (ja) | 2014-02-03 | 2017-07-12 | カディラ ヘルスケア リミティド | 新規複素環式化合物 |
KR20160117614A (ko) | 2014-02-21 | 2016-10-10 | 프린시피아 바이오파마, 인코퍼레이티드 | Btk 억제제의 염 및 고체 형태 |
SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
MA41265B1 (fr) | 2014-12-24 | 2023-05-31 | Principia Biopharma Inc | Compositions pour administration de médicaments iléo-jéjunal. |
PL3236953T3 (pl) | 2014-12-24 | 2021-04-19 | Principia Biopharma Inc. | Docelowe dawkowanie inhibitora btk |
EP3303334B1 (fr) | 2015-06-03 | 2021-06-02 | Principia Biopharma Inc. | Inhibiteurs de la tyrosine kinase |
WO2016210165A1 (fr) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Inhibiteurs de la tyrosine kinase |
CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
CN108349940B (zh) | 2015-10-14 | 2021-08-13 | 淄博百极常生制药有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
EP3478273A1 (fr) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc. | Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile |
-
2015
- 2015-12-18 SG SG11201704808VA patent/SG11201704808VA/en unknown
- 2015-12-18 MA MA41197A patent/MA41197B1/fr unknown
- 2015-12-18 PL PL15823107T patent/PL3233103T3/pl unknown
- 2015-12-18 EA EA201791243A patent/EA036269B1/ru not_active IP Right Cessation
- 2015-12-18 EP EP15823107.6A patent/EP3233103B1/fr active Active
- 2015-12-18 MX MX2017007973A patent/MX2017007973A/es unknown
- 2015-12-18 WO PCT/US2015/066868 patent/WO2016100914A1/fr active Application Filing
- 2015-12-18 CA CA2970723A patent/CA2970723C/fr active Active
- 2015-12-18 ES ES15823107T patent/ES2843323T3/es active Active
- 2015-12-18 BR BR112017013022A patent/BR112017013022A2/pt active Search and Examination
- 2015-12-18 AU AU2015364335A patent/AU2015364335B2/en active Active
- 2015-12-18 PT PT158231076T patent/PT3233103T/pt unknown
- 2015-12-18 US US15/537,294 patent/US10485797B2/en active Active
- 2015-12-18 CN CN201580076193.1A patent/CN107257686B/zh active Active
-
2017
- 2017-06-12 IL IL252839A patent/IL252839B/en active IP Right Grant
-
2019
- 2019-10-04 US US16/593,352 patent/US10946008B2/en active Active
-
2020
- 2020-11-05 AU AU2020264338A patent/AU2020264338A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2843323T3 (es) | 2021-07-16 |
US10946008B2 (en) | 2021-03-16 |
CN107257686A (zh) | 2017-10-17 |
US20180050027A1 (en) | 2018-02-22 |
AU2015364335A1 (en) | 2017-07-20 |
MX2017007973A (es) | 2018-02-09 |
EP3233103A1 (fr) | 2017-10-25 |
WO2016100914A1 (fr) | 2016-06-23 |
AU2015364335B2 (en) | 2020-11-26 |
CN107257686B (zh) | 2021-01-29 |
PL3233103T3 (pl) | 2021-04-19 |
PT3233103T (pt) | 2021-01-18 |
SG11201704808VA (en) | 2017-07-28 |
IL252839B (en) | 2021-03-25 |
EP3233103B1 (fr) | 2020-10-14 |
EA036269B1 (ru) | 2020-10-21 |
AU2020264338A1 (en) | 2020-12-03 |
CA2970723A1 (fr) | 2016-06-23 |
US10485797B2 (en) | 2019-11-26 |
IL252839A0 (en) | 2017-08-31 |
CA2970723C (fr) | 2023-09-05 |
US20200101059A1 (en) | 2020-04-02 |
EA201791243A1 (ru) | 2017-12-29 |
BR112017013022A2 (pt) | 2018-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41197B1 (fr) | Traitement de le pemphigus | |
MX2021004191A (es) | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. | |
MX2021001439A (es) | Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio. | |
MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
CY1110435T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια οφθαλμικων καταστασεων με παραγωγα ρετινολης | |
WO2018115097A9 (fr) | Composition ophtalmologique pour le traitement du syndrome de l'oeil sec | |
MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
MA38961A1 (fr) | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose | |
PH12017500927A1 (en) | Envenomation therapies and related pharmaceutical compositions, systems and kits | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
WO2014194254A9 (fr) | Traitement anticancer au moyen de modulateurs isoformes de la kinase p13 | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
MX360045B (es) | Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
MA41238A (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
NZ792518A (en) | Formulations for administration of eflornithine | |
PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
EA201171035A1 (ru) | Композиции, включающие модуляторы pde4, и способ их применения для лечения, профилактики и сопровождения туберкулеза | |
EA201791225A1 (ru) | Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей | |
MX2022000712A (es) | Moduladores de nlrp3. | |
MX2021004709A (es) | Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1. | |
MA41985B1 (fr) | Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux | |
WO2019004788A3 (fr) | Composition pharmaceutique comprenant de la broussochalcone a à titre de principe actif pour la prévention ou le traitement d'une maladie inflammatoire de l'intestin | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
MX2021008941A (es) | Moduladores gpr35. | |
MA39837B1 (fr) | Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 |